Table 3:

Univariate analysis of mutations of interest and clinical outcomes in the training cohort

	Frequency of Mutation (n=357)	Overall Response (n=329)	Overall survival (n=357)				Progression-free survival (n=357)
	n (%)	n (%)	Median, months (95% CI)	Event/total	HR (95% CI)	p value	Median, months (95% CI)	Event/Total	HR (95% CI)	p value
BAP1
Wild type	303 (85%)	94 (34%)	31.5 (26.6–35.7)	152/303	ref	..	10.7 (8.3–11.1)	186/303	ref	..
Mutant	54 (15%)	17 (32%)	22.1 (13.5–28.7)	36/54	1.51 (1.05–2.17)	0.0261	5.5 (4.2–10.9)	35/54	1.38 (0.96–1.98)	0.083
KDM5C
Wild type	315 (88%)	101 (35%)	27.7 (25.2–32.6)	167/315	ref	..	9.5 (8.3–11.0)	194/315	ref	..
Mutant	42 (12%)	10 (25%)	31.5 (18.9-not reached)	21/42	0.94 (0.60–1.48)	0.780	8.0 (5.6–14.1)	27/42	1.00 (0.67–1.50)	0.984
PBRM1
Wild type	197 (55%)	51 (28%)	23.8 (18.7–28.2)	116/197	ref	..	8.2 (5.5–8.4)	134/197	ref	..
Mutant	160 (45%)	60	35.5 (28.0-not reached)	72/160	0.63 (0.47–0.85)	0.0019	11.1 (9.5–16.5)	87/160	0.67 (0.51–0.88)	0.004
SETD2
Wild type	266 (75%)	83 (34%)	27.6 (24.2–31.6)	144/266	ref	..	10.0 (8.3–11.1)	169/266	ref	..
Mutant	91 (25%)	28 (34%)	32.0 (19.6-not reached)	44/91	0.86 (0.62–1.21)	0.395	9.0 (8.1–11.2)	52/91	0.92 (0.67–1.25)	0.582
TERT
Wild type	315 (88%)	102 (35%)	28.2 (26.2–34.9)	162/315	ref	..	9.5 (8.3–11.0)	197/315	ref	..
Mutant	42 (12%)	9 (26%)	25.2 (13.7–36.8)	26/42	1.26 (0.83–1.91)	0.274	8.3 (2.7–13.8)	24/42	1.16 (0.76–1.77)	0.501
TP53
Wild type	318 (89%)	102 (35%)	30.6 (27.2–35.7)	159/318	ref	..	10.6 (8.3–11.1)	193/318	ref	..
Mutant	39 (11%)	9 (27%)	13.3 (10.0–21.1)	29/39	2.23 (1.50–3.32)	<0.0001	5.5 (2.7–10.8)	28/39	1.42 (0.95–2.10)	0.09

All 357 evaluable patients in the training cohort were included. HR=hazard ratio.